TechnoVax, Inc., a biotechnology developer of novel vaccines was awarded a three-year $2.9 million SBIR phase II grant from the National Institutes of Health to further the development of its VLP-based, vaccine program. “This award and recognition from the NIH emphasizes the importance of the VLP technology and this support will allow us to complete preclinical development and move into clinical testing of our influenza VLP vaccine candidates, including our H1N1 swine flu vaccine,” stated Dr. Jose Galarza, CEO of TechnoVax. TechnoVax's Virus-Like Particle (VLP) technology is a novel way to produce vaccines against dangerous viruses because the VLPs contain no infectious material but are highly immunogenic. TechnoVax's VLP vaccine technology uses a cell-based system for production rather than the laborious chicken egg system. This technology can reduce production time, manufacturing steps and costs in a safer and controllable process, while increasing vaccine protection against multiple viruses.